PRU is a Zacks Rank #3 (Hold) stock, with a Value Style Score of A and VGM Score of A. Shares are currently trading at a forward P/E of 8.9X for the current fiscal year compared to the Insurance ...

The encouraging long-term efficacy and safety associated with nemolizumab (IL-31 inhibitor) in prurigo nodularis was supported by a second set of data showing long-term benefit in atopic dermatitis.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Prudential (PRU) have what it takes? Let's find out.

PRU Shares are Affordable. PRU shares are trading at a price to forward 12-months earnings of 7.34X, lower than the industry average of 8.91X, the Finance sector’s 16.21X and the Zacks S&P 500 ...

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis ...

Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia ...

The Sleep Disturbance Numerical Rating Scale: content validity, psychometric validation, and meaningful within-patient change in prurigo nodularis. Dermatol Ther (Heidelb) . 2023;13(7):1587-1602 ...

Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release ...

Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing ...